JSC Grindeks informs that the company successfully continues registration of Mildronate\u00ae in the People\u2019s Republic of China.<\/p>\n\n\n\n
Last week in China, Beijing Grindeks management representatives \u2013 Chairman of the Council Kirovs Lipmans, R&D Director Nilss Poritis and Head of Regulatory Affairs Department Linda Litina met with the management of China\u2019s State Food and Drug Agency, as well as medication registration and research specialists. The visit was also attended by Latvia\u2019s Ambassador to the People\u2019s Republic of China Ingrida Levrence and other representatives of the embassy.<\/p>\n\n\n\n
During the meeting, the registration process of Mildronate\u00ae was discussed, paying particular attention to the report on pharmacokinetics of the clinical trial of Mildronate\u00ae.<\/p>\n\n\n\n
Chairman of the Council of JSC Grindeks Kirovs Lipmans: \u201cMildronate\u00ae is the original product of Grindeks, with which we are purposefully going to enter the highly promising Chinese market. During the meeting, Chinese State Food and Drug Agency\u2019s management confirmed that Grindeks has fulfilled all the preconditions to open Mildronate\u00ae clinical trial. It is planned that in the near future Grindeks will start cooperation with several clinical research centers in China.\u201d<\/p>\n\n\n\n
Mildronate\u00ae is the main original product of Grindeks, and its main sales markets are Russia and other CIS countries. In 2010 an international clinical trial on the influence of the original product Mildronate\u00ae on the treatment of angina was successfully finished. Grindeks altogether invested 1.6 million lats in this research.<\/p>\n\n\n\n
To reduce the dominance of one product Grindeks has significantly increased turnover amount of other medications and active pharmaceutical ingredients in the product portfolio over the past years. Mildronate\u00ae proportion has fallen from 73% to 51%.<\/p>\n\n\n\n
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Product portfolio of Grindeks consists of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.<\/p>\n\n\n\n
Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. JSC Grindeks shares are listed in the Official List of \u201cNasdaq OMX Riga\u201d.<\/p>\n\n\n\n